Treatment of Prostate Cancer M1a (Nodal Metastases)
For patients with M1a prostate cancer (nodal metastases only), the recommended treatment is combination systemic therapy with ADT plus an androgen receptor pathway inhibitor (ARPI) such as abiraterone, apalutamide, darolutamide, or enzalutamide, with consideration of triplet therapy (ADT + docetaxel + ARPI) for fit patients, particularly those with high-volume disease. 1, 2
Systemic Therapy Approach
The 2025 NCCN Guidelines and 2023 ESMO recommendations strongly discourage ADT monotherapy for M1a disease unless clear contraindications to combination therapy exist 1, 2. The evidence-based options are:
First-Line Treatment Options:
Doublet Therapy (ADT + ARPI):
- ADT + abiraterone/prednisone
- ADT + apalutamide
- ADT + enzalutamide
- ADT + darolutamide
All four ARPIs are considered generally interchangeable by expert panels 1. These combinations demonstrated significant overall survival benefits in landmark trials like LATITUDE and STAMPEDE 1.
Triplet Therapy (for fit patients):
- ADT + docetaxel + abiraterone/prednisone (ESMO-MCBS score: 4) 2
- ADT + docetaxel + darolutamide (ESMO-MCBS score: 4) 2
Triplet therapy is particularly recommended for fit patients with de novo metastatic disease, especially those with multiple bone metastases (>3) or visceral metastases 2. While M1a disease is nodal-only, the fitness of the patient and disease burden should guide whether doublet or triplet therapy is chosen.
Important Caveats:
ADT monotherapy should only be used in:
- Vulnerable/frail patients who cannot tolerate treatment intensification 2
- Asymptomatic patients with life expectancy ≤5 years 1
Treatment intensification is strongly recommended because ADT alone is associated with inferior outcomes compared to combination approaches. The NCCN explicitly states that ADT monotherapy is "discouraged unless there are clear contraindications to combination therapy" 1.
Metastasis-Directed Therapy Considerations
For oligometastatic M1a disease (≤5 lymph nodes), metastasis-directed therapy (MDT) can be considered as part of a multimodal approach 1. The evidence suggests:
- Elective nodal radiotherapy (ENRT) may be superior to stereotactic body radiotherapy (SBRT) alone for nodal oligorecurrences, with fewer nodal relapses, though at higher toxicity (16% vs 5% late toxicity) 3
- The PEACE V-STORM trial showed no significant difference in acute toxicity between MDT alone versus ENRT + MDT for oligorecurrent nodal disease 4
- ENRT combined with short-course ADT demonstrated 5-year biochemical disease-free survival of 43% and distant progression-free survival of 58% 5
However, MDT should be considered adjunctive to systemic therapy, not a replacement. The primary treatment remains systemic combination therapy.
Practical Algorithm:
Assess patient fitness:
- Fit patient → Consider triplet therapy (ADT + docetaxel + ARPI)
- Standard fitness → Doublet therapy (ADT + ARPI)
- Frail/vulnerable → ADT monotherapy acceptable
Evaluate disease burden:
- Oligometastatic (≤5 nodes) → Add MDT consideration (preferably ENRT over focal SBRT)
- Multiple nodes → Systemic therapy alone
Select ARPI based on:
- Patient comorbidities and side effect profiles
- All four ARPIs are considered equivalent in efficacy 1
Add bone-protective therapy if indicated for elevated fracture risk 1
Common Pitfalls to Avoid:
- Do not use ADT monotherapy in fit patients with M1a disease—this represents undertreatment with inferior survival outcomes
- Do not rely solely on MDT without systemic therapy for M1a disease
- Do not use limited or standard extended lymph node dissection as salvage treatment—it is insufficient for nodal recurrences 6
- If using radiotherapy for oligometastatic nodes, prefer ENRT over focal SBRT to reduce nodal recurrence risk 3, 5
The treatment landscape has shifted dramatically toward treatment intensification, and the evidence consistently demonstrates that combination systemic therapy improves both progression-free and overall survival compared to ADT alone in metastatic hormone-sensitive prostate cancer.